Bilateral Subthalamotomy for PD (Movement Disorders Congress 2002)

Subject: Bilateral Subthalamotomy for PD (Movement Disorders Congress 2002)

Date: 11/29/2002

E-MOVE reports from the Seventh International Congress of Parkinson’s Disease and Movement Disorders, November 10-14 in Miami, Florida. Poster (P), platform session (PL), and page numbers are from Movement Disorders 2002;17(suppl 5).

Bilateral dorsal subthalamotomy in Parkinson's disease (PD): Initial response and evolution after 2 years
L Alvarez, R Macias, G Lopez, E Alvarez, C Maragoto, JA Obeso, N Pavon, MC Rodriguez-Oroz, J Juncos, J Guridi, ES Tolosa, W Koller, MR DeLong
P274;S95

Motor improvements from bilateral subthalamotomy are sustained for at least 2 years, according to this report.

Eighteen advanced PD patients received staged (n=7) or simultaneous bilateral subthalamotomy. One patient subsequently developed MSA signs and was excluded from further analysis. Motor improvements compared to baseline were 58% in the off state and 63% in the on state. Daily levodopa dose was reduced by a mean of 72%, with 5 patients receiving none. Effects on levodopa-related dyskinesias were variable, but improved 50% overall. Three patients developed severe chorea post-operatively, which improved spontaneously at 3-6 months.

An earlier report on this same cohort is archived at http://www.wemove.org/emove/article.asp?ID=329
----

2002 E-MOVE conference reports are made possible in part through unrestricted educational grants from these sponsors:
Gold Level: Bertek Pharmaceuticals, Elan Pharmaceuticals, Pharmacia Corporation.
Silver Level: GlaxoSmithKline, Amarin Pharmaceuticals
Bronze Level: Procter & Gamble Pharmaceuticals, Schwarz Pharma.